These cancer types should then really benefit from treatment with YAP1 inhibitors, as well as kidney renal clear cell carcinoma, head and neck carcinoma, bladder cancer and lower grade glioma, in which we found not only at least one Hippo gene as an independent prognostic factor, but also a correlation between the predictors and YAP1 protein levels, coherently with their role within Hippo pathway. This evidence concerns the gene YAP1 and urinary bladder carcinoma.